Sunitinib, as the anti-angiogenic drug, is a receptor tyrosine-kinase inhibitor and immunomodulator, that potently prevents MDSC accumulation and restores normal T-cell function in tumor-bearing mice, independent of its capacity to inhibit tumor progression, as well as reverses MDSC accumulation and T-cell inhibition even in the blood of non-responder renal cell carcinoma (RCC) patients (98). Here, NTRK1 is linked to renal cell carcinoma.